Autonomix medical, inc. completes $8,000,000 transaction for exclusive worldwide rights to technology for cardiology field use – over 100 patents in portfolio

Autonomix now wholly owns development and commercialization rights to its technology in all indications re-acquisition broadens autonomix's development and strategic opportunities the woodlands, tx, jan. 30, 2024 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has regained exclusive worldwide rights to its technology for cardiology field use from impulse medical, inc. in december 2021, autonomix granted impulse medical, inc., a license to its technology for use in the field of cardiology. in july 2023, the company entered into a termination agreement for the license agreement in exchange for the issuance, upon the closing of its initial public offering, of a warrant to purchase the number of shares of common stock based upon a fixed value of $8 million divided by the price per share in the offering.
AMIX Ratings Summary
AMIX Quant Ranking